1. The Prognostic Value of Immunophenotypic Characteristics of Plasma Cells in Newly Diagnosed Multiple Myeloma Patients Treated with First-Generation Proteasome Inhibitor Bortezomib
   Galina Nikolaevna Salogub et al, 2022, Clinical oncohematology CrossRef
2. CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome
   Epameinondas Koumpis et al, 2021, Pathology - Research and Practice CrossRef
3. Clinical effects of CD45 on the prognosis of extramedullary myeloma relapse
   Satoko Oka et al, 2020, Journal of Clinical Pharmacy and Therapeutics CrossRef
4. MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy
   Kazuya Kurihara et al, 2019, Medical Oncology CrossRef
5. Prognostic significance of CD56 expression in patients with multiple myeloma: a meta-analysis
   Lijuan Zhang et al, 2022, Hematology CrossRef
6. Immunophenotypic Profile and Measurable Residual Disease Monitoring in Multiple Myeloma: A Prospective Study From a Tertiary Care Centre in Southern India
   Pandurangan Sathya et al, 2024, Cureus CrossRef
7. Relevance of diffusion-weighted imaging with background body signal suppression for staging, prognosis, morphology, treatment response, and apparent diffusion coefficient in plasma-cell neoplasms: A single-center, retrospective study
   Akiko Yamada et al, 2021, PLOS ONE CrossRef
8. Prognostic Relevance of Concordant Expression CD69 and CD56 in Response to Bortezomib Combination Therapy in Multiple Myeloma Patients
   Nadia ElMenshawy et al, 2021, Cancer Investigation CrossRef